Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has given Mylan Laboratories tentative approval for its abbreviated new drug application for a 2.5mg generic version of Novartis' breast cancer drug Femara.
Subscribe to our email newsletter
Femara tablets had US sales of approximately $326 million for the same strength for 2006, according to IMS Health.
However, Novartis plans to defend its intellectual property rights against Mylan, according to Reuters. Novartis has a compound patent on Femara until 2011 and filed a patent infringement lawsuit against Mylan’s generic version in 2006.